Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities

Molecular Therapy - Oncolytics - Tập 14 - Trang 66-73 - 2019
Jiayu Liu1, Xiaoqiong Wu1, Limin Lin1, Haitao Pan1, Yanlan Wang1, Yumei Li1, Yining Zhao1, Zhong Wang1
1School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, China

Tài liệu tham khảo

Owen, 2013, Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles, J. Control. Release, 172, 395, 10.1016/j.jconrel.2013.07.011

Slamon, 1987, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science, 235, 177, 10.1126/science.3798106

Yoshida, 1989, Amplification of epidermal growth factor receptor (EGFR) gene and oncogenes in human gastric carcinomas, Virchows Arch. B Cell Pathol. Incl. Mol. Pathol., 57, 285, 10.1007/BF02899093

Xia, 1997, Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma, Clin. Cancer Res., 3, 3

Weiner, 1990, Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung, Cancer Res., 50, 421

Schneider, 1989, Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer, Cancer Res., 49, 4968

Hou, 1992, Oral cancer progression and c-erbB-2/neu proto-oncogene expression, Cancer Lett., 65, 215, 10.1016/0304-3835(92)90234-M

Greally, 2018, HER2: An emerging target in colorectal cancer, Curr. Probl. Cancer, 42, 560, 10.1016/j.currproblcancer.2018.07.001

Pondé, 2018, Treatment of advanced HER2-positive breast cancer: 2018 and beyond, Cancer Treat. Rev., 67, 10, 10.1016/j.ctrv.2018.04.016

Valabrega, 2007, Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer, Ann. Oncol., 18, 977, 10.1093/annonc/mdl475

Nahta, 2006, Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer, Nat. Clin. Pract. Oncol., 3, 269, 10.1038/ncponc0509

Wu, 2018, A Single Domain-Based Anti-Her2 Antibody Has Potent Antitumor Activities, Transl. Oncol., 11, 366, 10.1016/j.tranon.2018.01.024

Lin, 2018, A HER2 bispecific antibody can be efficiently expressed in Escherichia coli with potent cytotoxicity, Oncol. Lett., 16, 1259

Zhu, 2014, Site-specific antibody-drug conjugation through an engineered glycotransferase and a chemically reactive sugar, MAbs, 6, 1190, 10.4161/mabs.29889

Ritchie, 2013, Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates, MAbs, 5, 13, 10.4161/mabs.22854

Baselga, 2012, Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer, N. Engl. J. Med., 366, 109, 10.1056/NEJMoa1113216

Blumenthal, 2013, First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer, Clin. Cancer Res., 19, 4911, 10.1158/1078-0432.CCR-13-1212

Geuijen, 2018, Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade, Cancer Cell, 33, 922, 10.1016/j.ccell.2018.04.003

Hausman, 2017, Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers, J. Clin. Oncol., 35

Huang, 2018, Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody, MAbs, 10, 864, 10.1080/19420862.2018.1486946

Croset, 2014, 139 GBR1302: a BEAT® bispecific antibody for the treatment of HER2 positive cancers, Eur. J. Cancer, 50, 48, 10.1016/S0959-8049(14)70265-5

Li, 2016, A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells, AMB Express, 6, 32, 10.1186/s13568-016-0201-4

Xing, 2017, BiHC, a T-Cell-Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells, Transl. Oncol., 10, 780, 10.1016/j.tranon.2017.07.003

Deng, 2018, A Bispecific Antibody Based on Pertuzumab Fab Has Potent Antitumor Activity, J. Immunother., 41, 1, 10.1097/CJI.0000000000000200

Li, 2016, A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy, Cancer Cell, 29, 117, 10.1016/j.ccell.2015.12.008

Skrlj, 2010, Single-chain Fv antibody fragments retain binding properties of the monoclonal antibody raised against peptide P1 of the human prion protein, Appl. Biochem. Biotechnol., 160, 1808, 10.1007/s12010-009-8699-4

Freiherr von Roman, 2014, Improved extracellular expression and purification of recombinant Staphylococcus aureus protein A, Protein Expr. Purif., 93, 87, 10.1016/j.pep.2013.10.013

Jones, 2009, Evolving novel anti-HER2 strategies, Lancet Oncol., 10, 1179, 10.1016/S1470-2045(09)70315-8

Riccio, 2017, Superior Suppression of ErbB2-positive Tumor Cells by a Novel Human Triparatopic Tribody, J. Immunother., 40, 117, 10.1097/CJI.0000000000000152

Ritter, 2007, Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network, Clin. Cancer Res., 13, 4909, 10.1158/1078-0432.CCR-07-0701

Brack, 2014, A bispecific HER2-targeting FynomAb with superior antitumor activity and novel mode of action, Mol. Cancer Ther., 13, 2030, 10.1158/1535-7163.MCT-14-0046-T

LoRusso, 2016, Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors, J. Clin. Oncol., 34, 3803, 10.1200/JCO.2014.59.0018

LoRusso, 2011, Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer, Clin. Cancer Res., 17, 6437, 10.1158/1078-0432.CCR-11-0762

Burris, 2011, Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer, Clin. Breast Cancer, 11, 275, 10.1016/j.clbc.2011.03.018

Wu, 2018, T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics, Pharmacol. Ther., 182, 161, 10.1016/j.pharmthera.2017.08.005

Schoonjans, 2000, Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives, J. Immunol., 165, 7050, 10.4049/jimmunol.165.12.7050

Byrne, 2013, A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications, Trends Biotechnol., 31, 621, 10.1016/j.tibtech.2013.08.007

Rozan, 2013, Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells, Mol. Cancer Ther., 12, 1481, 10.1158/1535-7163.MCT-12-1012

Li, 2015, A novel bispecific antibody, S-Fab, induces potent cancer cell killing, J. Immunother., 38, 350, 10.1097/CJI.0000000000000099

Swain, 2015, Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer, N. Engl. J. Med., 372, 724, 10.1056/NEJMoa1413513

Swain, 2013, Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study, Lancet Oncol., 14, 461, 10.1016/S1470-2045(13)70130-X

Rockberg, 2009, Discovery of epitopes for targeting the human epidermal growth factor receptor 2 (HER2) with antibodies, Mol. Oncol., 3, 238, 10.1016/j.molonc.2009.01.003

Even-Desrumeaux, 2012, Single-domain antibodies: a versatile and rich source of binders for breast cancer diagnostic approaches, Mol. Biosyst., 8, 2385, 10.1039/c2mb25063b

Kwong, 2009, E. coli expression and purification of Fab antibody fragments, Curr. Protoc. Protein Sci., Chapter 6

Pan, 2018, Site-specific PEGylation of an anti-CEA/CD3 bispecific antibody improves its antitumor efficacy, Int. J. Nanomedicine, 13, 3189, 10.2147/IJN.S164542

Thông tin
Thông tin xuất bản

Molecular Therapy - Oncolytics

Tập 14

66-73

Thông tin tác giả